Intravitreal stories

Oct 28, 2026

SAR402663 gene therapy shows 97% reduction in treatment burden for wet AMD in phase 2 trial

A phase 2 study presented in Vienna showed that SAR402663, a single intravitreal gene therapy injection for wet age-related macular degeneration, achieved a 97% reduction in treatment burden with positive efficacy and safety results. More than 90% of patients responded to the medium dose treatment.

Oct 28, 20262 sources

Top claims

▪Pooled phase 1 and phase 2 data for Sanofi's SAR402663 showed few cases of intraocular inflammation, all of which were manageable with corticosteroids, including one event that resolved spontaneously.
▪To mitigate immune-mediated safety risks associated with gene therapies, the SAR402663 trial protocol incorporated a 19-week prophylactic regimen of corticosteroids.
▪Phase 2 interim results for Sanofi's SAR402663 gene therapy showed both evaluated doses were well tolerated with no reported cases of endophthalmitis, vasculitis, hypotony, or choroidal effusions.

Subtopics

Clinical trials1 Drug development1 Drug safety1 Gene therapy1 Wet AMD1

Related timelines